Genomic strategies for personalized cancer therapy.

Numerous recent studies have demonstrated the use of genomic data, particularly gene expression signatures, as clinical prognostic factors in cancer and other complex diseases. These studies highlight the opportunity for strategies to achieve truly personalized cancer treatment. In particular, the ability to develop gene expression signatures will likely allow us to guide the use of currently available cancer drugs, develop new targeted therapeutics, and provide an opportunity to better match the most effective drug or drugs with the molecular characteristics of the individual patient.

[1]  Alan Ashworth,et al.  Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance , 2006, Breast Cancer Research and Treatment.

[2]  H. Dressman,et al.  Genomic signatures to guide the use of chemotherapeutics , 2006, Nature Medicine.

[3]  J. Nevins,et al.  Linking oncogenic pathways with therapeutic opportunities , 2006, Nature Reviews Cancer.

[4]  Gary H Lyman,et al.  Gene expression profile assays as predictors of recurrence-free survival in early-stage breast cancer: a metaanalysis. , 2006, Clinical breast cancer.

[5]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[6]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[7]  J. Mesirov,et al.  Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. , 1999, Science.

[8]  Syed Mohsin,et al.  Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.

[9]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[10]  A. Witteveen,et al.  Converting a breast cancer microarray signature into a high-throughput diagnostic test , 2006, BMC Genomics.

[11]  J. Sparano,et al.  TAILORx: trial assigning individualized options for treatment (Rx). , 2006, Clinical breast cancer.

[12]  D. Penson,et al.  Predictors of overall and cancer-free survival of patients with localized prostate cancer treated with primary androgen suppression therapy: results from the prostate cancer outcomes study. , 2007, The Journal of urology.

[13]  M. Relling,et al.  Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. , 2005, Cancer cell.

[14]  Yudong D. He,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[15]  J. Astola,et al.  Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. , 2005, Gastroenterology.

[16]  G. Ross,et al.  Long-term survival in a phase III, randomised study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  N. Robert,et al.  Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Anil Potti,et al.  An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Lyndsay N Harris,et al.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Ross,et al.  Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Lander,et al.  A molecular signature of metastasis in primary solid tumors , 2003, Nature Genetics.

[22]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[23]  Fei Huang,et al.  Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. , 2007, Cancer research.

[24]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[25]  Cheng Cheng,et al.  Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. , 2004, The New England journal of medicine.

[26]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  P. Brown,et al.  Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Cronin,et al.  A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.

[29]  R. Marks,et al.  Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Mukherjee,et al.  A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. , 2006, The New England journal of medicine.

[31]  Marc Buyse,et al.  Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial , 2006, Nature Clinical Practice Oncology.

[32]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[33]  C. Denkert,et al.  Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations , 2006, International journal of cancer.

[34]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.